Abstract:Systemic mastocytosis (SM) is a subset of rare neoplasms characterized by clonal proliferation of aberrant mast cells (MCs) and their accumulation in >= 1 extracutaneous organs, which typically associates with activating KIT mutations.(1) SM with an associated hematological neoplasm (AHN) is the second most common type of SM in Mayo series (similar to 40%),(2) with challenging diagnosis because the mast cell infiltration may hide behind the AHN component and vice versa.(3-5) This is particularly applicable to acute myeloid leukemia (AML) because the histological examination of bone marrow (BM) has not been established as a standard diagnostic tool. Moreover, the concomitant hematological neoplasm often shares a KIT mutation and/or other clonal genetic abnormalities with neoplastic MCs. AML with t(8;21) (q22;q22)/RUNX1::RUNX1T1 [t(8;21) AML] represents 4% to 8% of all AMLs, which is categorized to the genetically favorable risk group.(6) Meanwhile, KIT mutations, most frequently at position D816, are detectable in up to 20% to 47% of patients with t(8;21) AML and associate with decreased remission duration and inferior overall survival (OS).(7-10) Previous case reports, case-series, and/or literature reviews have described the potential association of KIT mutant t(8;21) AML [KITpos t(8;21) AML] with underlying SM.(11)(,)(12) Owing to a lack of literature on investigating similarities and differences between SM-t(8;21) AML and KITpos t(8;21) AML, we carried out this retrospective cohort study from multiple Chinese centers to compare clinical and molecular features between these 2 groups. Between January 2009 and December 2022, 24 patients with SM-t(8;21) AML and 212 with KITpos t(8;21) AML diagnosed and treated in 16 Chinese centers were eligible. All patients were screened for SM by BM smear, flow cytometry, and/or BM histological examination. Details of the study design, patient population, treatment regimen, and statistical analysis have been described in supplemental Data. This study was approved by the responsible ethics committees and performed in accordance with the Declaration of Helsinki.

A Multicenter Retrospective Comparison Between Systemic Mastocytosis with T(8;21) AML and KIT Mutant T(8;21) AML.

A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML

Acute Myeloid Leukemia with T(8;21)(q22;q22.1)/runx1-Runx1t1 and KIT Exon 8 Mutation is Associated with Characteristic Mastocytosis and Dismal Outcomes

Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with RUNX1::RUNX1T1

[Cytogenetic Analysis of 154 Case of Acute Myeloid Leukemia with T(8;21)].

Systemic mastocytosis with an associated hematological neoplasm (acute myeloid leukaemia with RUNX1::RUNX1T1 fusion) – A case study

Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow

Systemic Mastocytosis Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: a Case Report

T-cell immune profile in blood of systemic mastocytosis: Association with disease features

MASTering systemic mastocytosis: Lessons learned from a large patient cohort

A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis

Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation

SOHO State of the Art Update and Next Questions | Current and Emerging Therapies for Systemic Mastocytosis

[Clinical and Experimental Characteristics of 20 Patients with Acute Myeloid Leukemia with Complex Variant of T(8; 21)].

Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity

How I diagnose systemic mastocytosis

Mast cell sarcoma with KIT p.D816V mutation and concurrent systemic mastocytosis

Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis

Advanced systemic mastocytosis-Revised classification, new drugs and how we treat